"immune checkpoint inhibitor" trang 2 - tải miễn phí từ tailieunhanh
Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
5    41    1
Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
8    46    1
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors
10    40    1
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea
9    45    1
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
11    58    1
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
16    37    1
Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
8    37    1
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
18    74    1
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
14    59    1
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
28    21    1
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study
9    29    1
Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort

Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
10    27    1
Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: A retrospective cohort study

Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: A retrospective cohort study
10    17    1
Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma
10    18    1
Ipilimumab-and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: A case report

Ipilimumab-and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: A case report
7    1    1
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study
6    1    1
Management of metastatic melanoma in Texas: Disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors

Management of metastatic melanoma in Texas: Disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors
11    1    1
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%
12    1    1
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
10    1    1
Total serum N‑glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Total serum N‑glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
12    6    1